Junya Hashimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junya Hashimoto has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Ken Sakai
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
8 shared publications- Masaki Muramatsu
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
5 shared publications - Yuko Hamasaki
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
5 shared publications Takeshi Kawamura
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
4 shared publicationsYoshihiro Itabashi
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
4 shared publications- Hideyo Oguchi
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
3 shared publications
Latest Publications
- 2 September 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (5) , 136
Experience with early treatment using febuxostat in a patient with adenine phosphoribosyltransferase deficiency after pediatric kidney transplantation: a case report
- 2 September 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (5) , 136
Experience with early treatment using febuxostat in a patient with adenine phosphoribosyltransferase deficiency after pediatric kidney transplantation: a case report
- 1 August 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 22-28
Clinicopathological Analysis of Collapsing Focal Segmental Glomerulosclerosis after Kidney Transplantation
Introduction: There is limited evidence regarding collapsing focal segmental glomerulosclerosis (cFSGS) after kidney transplantation. The aim of this study was to clarify the clinicopathological character of cFSGS. Methods: Forty-two biopsies from 35 patients with cFSGS were included in the study. The cFSGS variant was determined according to the Colombia classification. The scoring of arteriosclerosis was evaluated as a score of 0–3 on the basis of the intimal fibrous thickening divided by the media, and other histological scoring was evaluated using the Banff score. Biopsies with a sclerosis score ≥3/4 were excluded from the study. Multivariate analysis was performed by a forward selection method using covariates significantly associated with cFSGS biopsies. Results: Of 42 biopsies diagnosed with FSGS, 19 (45.2%) biopsies were cFSGS and 23 (54.8%) were non-collapsing FSGS (ncFSGS). The cFSGS group had a longer time after transplantation, lower eGFR, higher urine protein levels, and higher systolic blood pressure (all statistically significant) compared with the ncFSGS group. The Banff aah, ci, and arteriosclerosis scores were significantly higher in the cFSGS group compared with the ncFSGS group. There were no significant differences in the donor age or arteriosclerosis in 1-h biopsies between groups. Multivariate analysis showed that the arteriosclerosis score and Banff ci score were significantly associated with cFSGS using covariates that were statistically significant-related factors including systolic blood pressure, eGFR, proteinuria, ci score, aah score, and arteriosclerosis score. Graft survival after the time of biopsy was significantly worse in the cFSGS group compared with the ncFSGS group. Conclusion: Collapsing FSGS was poor prognostic factor for allograft survival. Arteriosclerosis and chronic interstitial fibrosis may be related to cFSGS after kidney transplantation.
- 1 August 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 22-28
Clinicopathological Analysis of Collapsing Focal Segmental Glomerulosclerosis after Kidney Transplantation
Introduction: There is limited evidence regarding collapsing focal segmental glomerulosclerosis (cFSGS) after kidney transplantation. The aim of this study was to clarify the clinicopathological character of cFSGS. Methods: Forty-two biopsies from 35 patients with cFSGS were included in the study. The cFSGS variant was determined according to the Colombia classification. The scoring of arteriosclerosis was evaluated as a score of 0–3 on the basis of the intimal fibrous thickening divided by the media, and other histological scoring was evaluated using the Banff score. Biopsies with a sclerosis score ≥3/4 were excluded from the study. Multivariate analysis was performed by a forward selection method using covariates significantly associated with cFSGS biopsies. Results: Of 42 biopsies diagnosed with FSGS, 19 (45.2%) biopsies were cFSGS and 23 (54.8%) were non-collapsing FSGS (ncFSGS). The cFSGS group had a longer time after transplantation, lower eGFR, higher urine protein levels, and higher systolic blood pressure (all statistically significant) compared with the ncFSGS group. The Banff aah, ci, and arteriosclerosis scores were significantly higher in the cFSGS group compared with the ncFSGS group. There were no significant differences in the donor age or arteriosclerosis in 1-h biopsies between groups. Multivariate analysis showed that the arteriosclerosis score and Banff ci score were significantly associated with cFSGS using covariates that were statistically significant-related factors including systolic blood pressure, eGFR, proteinuria, ci score, aah score, and arteriosclerosis score. Graft survival after the time of biopsy was significantly worse in the cFSGS group compared with the ncFSGS group. Conclusion: Collapsing FSGS was poor prognostic factor for allograft survival. Arteriosclerosis and chronic interstitial fibrosis may be related to cFSGS after kidney transplantation.
- Open Access
- 14 March 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-7
Acute kidney injury caused by ureteral obstruction after Deflux® injection treatment for vesicoureteral reflux after pediatric kidney transplantation: a case report
Background: Vesicoureteral reflux (VUR) after pediatric kidney transplantation (KT) is a frequent urologic complication. Endoscopic Deflux® injection is a treatment option. However, ureteral obstruction after Deflux® injection treatment is a potential complication that may have serious outcomes for patients who have undergone KT. We report a case of acute kidney injury (AKI) caused by ureteral obstruction with acute foreign body reaction immediately after Deflux® injection treatment for VUR after transplantation. Case presentation: We encountered a 5-year-old boy who underwent living-donor KT at age 4 years because of end-stage kidney disease caused by posterior urethral valves. At 4 months after KT, VUR (grade IV) and bladder dysfunction worsening were detected by voiding cystourethrography. A second febrile urinary tract infection (UTI) was treated with endoscopic Deflux® injection in the neo-orifice of the transplanted kidney after 2 weeks of antimicrobial therapy. Postoperatively, the patient experienced a temporary decrease in urine output. Increased creatinine was observed on postoperative day 1. The renal pelvis was more dilated than it was preoperatively, and ureteral dilatation was observed. A bulge associated with Deflux® injection, consistent with the injection site, was observed in the bladder. Additionally, because the graft function continued to decline, AKI associated with ureteral obstruction after Deflux® injection treatment was diagnosed, and a ureteral stent was placed on postoperative day 4. The graft function gradually recovered. Four months later, the ureteral stent was removed. Exacerbation of hydronephrosis of the transplanted kidney was not observed, and the graft function was stable. Although the patient experienced residual VUR after KT, excretion control was continued and UTI recurrence was not observed. Conclusions: Ureteral obstruction after Deflux® injection treatment for VUR after transplantation is a serious complication; therefore, treatment indications and timing should be carefully considered.
- 14 March 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-7
Open AccessAcute kidney injury caused by ureteral obstruction after Deflux® injection treatment for vesicoureteral reflux after pediatric kidney transplantation: a case report
Background: Vesicoureteral reflux (VUR) after pediatric kidney transplantation (KT) is a frequent urologic complication. Endoscopic Deflux® injection is a treatment option. However, ureteral obstruction after Deflux® injection treatment is a potential complication that may have serious outcomes for patients who have undergone KT. We report a case of acute kidney injury (AKI) caused by ureteral obstruction with acute foreign body reaction immediately after Deflux® injection treatment for VUR after transplantation. Case presentation: We encountered a 5-year-old boy who underwent living-donor KT at age 4 years because of end-stage kidney disease caused by posterior urethral valves. At 4 months after KT, VUR (grade IV) and bladder dysfunction worsening were detected by voiding cystourethrography. A second febrile urinary tract infection (UTI) was treated with endoscopic Deflux® injection in the neo-orifice of the transplanted kidney after 2 weeks of antimicrobial therapy. Postoperatively, the patient experienced a temporary decrease in urine output. Increased creatinine was observed on postoperative day 1. The renal pelvis was more dilated than it was preoperatively, and ureteral dilatation was observed. A bulge associated with Deflux® injection, consistent with the injection site, was observed in the bladder. Additionally, because the graft function continued to decline, AKI associated with ureteral obstruction after Deflux® injection treatment was diagnosed, and a ureteral stent was placed on postoperative day 4. The graft function gradually recovered. Four months later, the ureteral stent was removed. Exacerbation of hydronephrosis of the transplanted kidney was not observed, and the graft function was stable. Although the patient experienced residual VUR after KT, excretion control was continued and UTI recurrence was not observed. Conclusions: Ureteral obstruction after Deflux® injection treatment for VUR after transplantation is a serious complication; therefore, treatment indications and timing should be carefully considered.
- 15 June 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 14-21
Mesangiolysis in Pathological Chronic Active Antibody-Mediated Rejection in Kidney Transplant Biopsies
Introduction: This study aimed to determine if immune or nonimmune and acute or chronic lesions associated with mesangiolysis (MGLS) occurred in biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR) in kidney transplant biopsies. Methods: We evaluated MGLS in 41 patients with biopsy findings of P-CAABMR from January 2016 to December 2019. Histological scoring was evaluated by Banff classification. Multivariate logistic regression analysis was performed using a forward selection method. Results: Fifteen of the 41 P-CAABMR biopsies (36.6%) cases showed MGLS. The estimated glomerular filtration rate (eGFR) was significantly lower in the MGLS-positive compared with the MGLS-negative group, and proteinuria was significantly higher in the MGLS-positive compared with the MGLS-negative group. In the clinical model, multivariate analysis was performed using covariates of eGFR and duration after transplantation significantly correlated with MGLS by simple analysis, in addition to type of calcineurin inhibitor use (tacrolimus or cyclosporine), donor-specific antibodies, diabetes, and hypertension grade defined by use of antihypertensive therapy or/and blood pressure level. Only hypertension grade was significantly correlated with MGLS. In the pathological model, multivariate analysis was performed using the presence of FSGS and the aah and cg scores significantly correlated with MGLS by simple analysis, in addition to g and ptc scores. The cg score was significantly correlated with hypertension grade, duration after transplantation, g, ah, and aah. Conclusion: Lower graft function and higher proteinuria was observed in MGLS of P-CAABMR. The Banff cg score was independently related to MGLS in multivariate analysis. Sustained glomerulitis, calcineurin inhibitor nephrotoxicity, and hypertension may cause Banff cg lesions, leading to MGLS in P-CAABMR.
- 15 June 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 14-21
Mesangiolysis in Pathological Chronic Active Antibody-Mediated Rejection in Kidney Transplant Biopsies
Introduction: This study aimed to determine if immune or nonimmune and acute or chronic lesions associated with mesangiolysis (MGLS) occurred in biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR) in kidney transplant biopsies. Methods: We evaluated MGLS in 41 patients with biopsy findings of P-CAABMR from January 2016 to December 2019. Histological scoring was evaluated by Banff classification. Multivariate logistic regression analysis was performed using a forward selection method. Results: Fifteen of the 41 P-CAABMR biopsies (36.6%) cases showed MGLS. The estimated glomerular filtration rate (eGFR) was significantly lower in the MGLS-positive compared with the MGLS-negative group, and proteinuria was significantly higher in the MGLS-positive compared with the MGLS-negative group. In the clinical model, multivariate analysis was performed using covariates of eGFR and duration after transplantation significantly correlated with MGLS by simple analysis, in addition to type of calcineurin inhibitor use (tacrolimus or cyclosporine), donor-specific antibodies, diabetes, and hypertension grade defined by use of antihypertensive therapy or/and blood pressure level. Only hypertension grade was significantly correlated with MGLS. In the pathological model, multivariate analysis was performed using the presence of FSGS and the aah and cg scores significantly correlated with MGLS by simple analysis, in addition to g and ptc scores. The cg score was significantly correlated with hypertension grade, duration after transplantation, g, ah, and aah. Conclusion: Lower graft function and higher proteinuria was observed in MGLS of P-CAABMR. The Banff cg score was independently related to MGLS in multivariate analysis. Sustained glomerulitis, calcineurin inhibitor nephrotoxicity, and hypertension may cause Banff cg lesions, leading to MGLS in P-CAABMR.
- Open Access
- 7 May 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 89-95
Vesicoureteral Reflux Causes Interstitial Inflammation in Pediatric Kidney Allograft: A Clinicopathological Analysis of 1-Year Protocol Biopsies
Introduction: At present, there is limited evidence of the histological impact of vesicoureteral reflux (VUR) on pediatric kidney allografts. In this study, we aimed to investigate the relationship between VUR diagnosed by voiding cystourethrography (VCUG) and 1-year protocol biopsy results. Methods: One hundred thirty-eight pediatric kidney transplantations were performed in Toho University Omori Medical Center between 2009 and 2019. We included 87 pediatric transplant recipients who were evaluated for VUR by VCUG prior to or at the time of the 1-year protocol biopsy and underwent a 1-year protocol biopsy after transplantation. We evaluated the clinicopathological findings of the VUR and non-VUR groups, and histological scores were evaluated using the Banff score. Tamm-Horsfall protein (THP) within the interstitium was identified by light microscopy. Results: Of the 87 transplant recipients, 18 cases (20.7%) were diagnosed with VUR by VCUG. The clinical background and findings were not significantly different between the VUR and non-VUR groups. The pathological findings revealed a significantly higher Banff total interstitial inflammation (ti) score in the VUR group than in the non-VUR group. Multivariate analysis indicated a significant relationship between the Banff ti score and THP within the interstitium, and VUR. The 3-year protocol biopsy results (n = 68) revealed a significantly higher Banff interstitial fibrosis (ci) score in the VUR group than in the non-VUR group. Conclusion: VUR caused interstitial fibrosis in the 1-year pediatric protocol biopsies, and interstitial inflammation at the 1-year protocol biopsy may affect interstitial fibrosis at the 3-year protocol biopsy.
- 7 May 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 89-95
Open AccessVesicoureteral Reflux Causes Interstitial Inflammation in Pediatric Kidney Allograft: A Clinicopathological Analysis of 1-Year Protocol Biopsies
Introduction: At present, there is limited evidence of the histological impact of vesicoureteral reflux (VUR) on pediatric kidney allografts. In this study, we aimed to investigate the relationship between VUR diagnosed by voiding cystourethrography (VCUG) and 1-year protocol biopsy results. Methods: One hundred thirty-eight pediatric kidney transplantations were performed in Toho University Omori Medical Center between 2009 and 2019. We included 87 pediatric transplant recipients who were evaluated for VUR by VCUG prior to or at the time of the 1-year protocol biopsy and underwent a 1-year protocol biopsy after transplantation. We evaluated the clinicopathological findings of the VUR and non-VUR groups, and histological scores were evaluated using the Banff score. Tamm-Horsfall protein (THP) within the interstitium was identified by light microscopy. Results: Of the 87 transplant recipients, 18 cases (20.7%) were diagnosed with VUR by VCUG. The clinical background and findings were not significantly different between the VUR and non-VUR groups. The pathological findings revealed a significantly higher Banff total interstitial inflammation (ti) score in the VUR group than in the non-VUR group. Multivariate analysis indicated a significant relationship between the Banff ti score and THP within the interstitium, and VUR. The 3-year protocol biopsy results (n = 68) revealed a significantly higher Banff interstitial fibrosis (ci) score in the VUR group than in the non-VUR group. Conclusion: VUR caused interstitial fibrosis in the 1-year pediatric protocol biopsies, and interstitial inflammation at the 1-year protocol biopsy may affect interstitial fibrosis at the 3-year protocol biopsy.
- 5 December 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (2) , e14440
Fibroblast growth factor 23‐Klotho and mineral metabolism in the first year after pediatric kidney transplantation: A single‐center prospective study
Background: The role of fibroblast growth factor 23 (FGF23) levels in mineral metabolism before and after kidney transplantation in pediatric patients is poorly understood.Methods: We prospectively evaluated 24 patients under 18 years of age (4.5 [3.3–9.8] years) who underwent living kidney transplantation between July 2016 and March 2018, and measured intact FGF23 and serum αKlotho levels, and other parameters of mineral metabolism before and after transplantation (Day 7, 1 and 4 months, and 1 year). Relationships between parameters were examined by linear analysis.Results: FGF23 level was 440.8 [63.4–5916.3] pg/ml pre‐transplant and decreased significantly to 37.1 [16.0–71.5] pg/ml at Day 7 post‐transplant (−91.6%, p < .001). Thereafter, it remained at normal levels until 1 year. αKlotho level was 785 [568–1292] pg/ml pre‐transplant and remained low at Day 7 and 1 month post‐transplant, with an increasing trend at 4 months. Post‐transplant phosphorus levels were significantly decreased compared with pre‐transplant, with a lowest level of 1.7 [1.3–2.9] mg/dl, −5.7 [−6.8, −3.8] SD at Day 4, followed by gradual recovery. Phosphorus levels and the ratio of tubular maximum phosphate reabsorption were significantly and negatively associated with pre‐transplant FGF23 until 4 months of post‐transplant. Pre‐transplant αKlotho was negatively associated with pre‐transplant FGF23 but not FGF23 or other parameters after transplantation.Conclusion: FGF23 in pediatric kidney transplant patients decreased rapidly after transplantation and associated with post‐transplant hypophosphatemia and increased phosphorus excretion. Post‐transplant αKlotho was low early post‐transplant but tended to increase subsequently. Post‐transplant αKlotho was unaffected by pre‐transplant FGF23 or other factors, suggesting pre‐transplant chronic kidney disease status has no effect.
- 5 December 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (2) , e14440
Fibroblast growth factor 23‐Klotho and mineral metabolism in the first year after pediatric kidney transplantation: A single‐center prospective study
Background: The role of fibroblast growth factor 23 (FGF23) levels in mineral metabolism before and after kidney transplantation in pediatric patients is poorly understood.Methods: We prospectively evaluated 24 patients under 18 years of age (4.5 [3.3–9.8] years) who underwent living kidney transplantation between July 2016 and March 2018, and measured intact FGF23 and serum αKlotho levels, and other parameters of mineral metabolism before and after transplantation (Day 7, 1 and 4 months, and 1 year). Relationships between parameters were examined by linear analysis.Results: FGF23 level was 440.8 [63.4–5916.3] pg/ml pre‐transplant and decreased significantly to 37.1 [16.0–71.5] pg/ml at Day 7 post‐transplant (−91.6%, p < .001). Thereafter, it remained at normal levels until 1 year. αKlotho level was 785 [568–1292] pg/ml pre‐transplant and remained low at Day 7 and 1 month post‐transplant, with an increasing trend at 4 months. Post‐transplant phosphorus levels were significantly decreased compared with pre‐transplant, with a lowest level of 1.7 [1.3–2.9] mg/dl, −5.7 [−6.8, −3.8] SD at Day 4, followed by gradual recovery. Phosphorus levels and the ratio of tubular maximum phosphate reabsorption were significantly and negatively associated with pre‐transplant FGF23 until 4 months of post‐transplant. Pre‐transplant αKlotho was negatively associated with pre‐transplant FGF23 but not FGF23 or other parameters after transplantation.Conclusion: FGF23 in pediatric kidney transplant patients decreased rapidly after transplantation and associated with post‐transplant hypophosphatemia and increased phosphorus excretion. Post‐transplant αKlotho was low early post‐transplant but tended to increase subsequently. Post‐transplant αKlotho was unaffected by pre‐transplant FGF23 or other factors, suggesting pre‐transplant chronic kidney disease status has no effect.
- Open Access
- 20 November 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (Suppl. 1) , 79-85
Clinicopathological Analysis of Medullary Ray Injury in 1-Year Protocol Paediatric Renal Allograft Biopsies
Aim: Medullary ray injury was recently reported in renal transplant biopsies. This study was performed to clarify the clinicopathological features of medullary ray injury in paediatric living renal transplant recipients. Methods: Paediatric recipients who completed a 5-year follow-up after living renal transplantation were enroled. We evaluated the clinical and pathological parameters of the presence or absence of medullary ray injury in their 1-year protocol biopsies. Results: Of 48 1-year protocol biopsies, 18 (37.5%) showed histological evidence of medullary ray injury. The 48 paediatric recipients were classified as those with medullary ray injury (n = 18; MRI-1Y [+] group) and those without medullary ray injury (n = 30; MRI-1Y [−] group) in the 1-year protocol biopsies. The prevalence of histological evidence of calcineurin inhibitor (CNI) nephrotoxicity, chronic obstruction or reflux nephropathy, and imaging findings of vesicoureteral reflux was 66.7, 22.2, and 7.7% in the MRI-1Y (+) group and 33.3, 13.3, and 15.4% in the MRI-1Y (−) group, respectively. Only the prevalence of CNI nephrotoxicity was significantly different between the 2 groups. There was no significant difference in the mean estimated glomerular filtration rate at 1, 3, or 5 years after transplantation between the 2 groups. Conclusion: In total, 37.5% of 1-year protocol biopsies showed histological evidence of medullary ray injury. This finding suggests that CNI nephrotoxicity might be the main contributor to medullary ray injury in 1-year protocol biopsies. The presence of medullary ray injury had little influence on renal function, at least during the first 5 years after transplantation.
- 20 November 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (Suppl. 1) , 79-85
Open AccessClinicopathological Analysis of Medullary Ray Injury in 1-Year Protocol Paediatric Renal Allograft Biopsies
Aim: Medullary ray injury was recently reported in renal transplant biopsies. This study was performed to clarify the clinicopathological features of medullary ray injury in paediatric living renal transplant recipients. Methods: Paediatric recipients who completed a 5-year follow-up after living renal transplantation were enroled. We evaluated the clinical and pathological parameters of the presence or absence of medullary ray injury in their 1-year protocol biopsies. Results: Of 48 1-year protocol biopsies, 18 (37.5%) showed histological evidence of medullary ray injury. The 48 paediatric recipients were classified as those with medullary ray injury (n = 18; MRI-1Y [+] group) and those without medullary ray injury (n = 30; MRI-1Y [−] group) in the 1-year protocol biopsies. The prevalence of histological evidence of calcineurin inhibitor (CNI) nephrotoxicity, chronic obstruction or reflux nephropathy, and imaging findings of vesicoureteral reflux was 66.7, 22.2, and 7.7% in the MRI-1Y (+) group and 33.3, 13.3, and 15.4% in the MRI-1Y (−) group, respectively. Only the prevalence of CNI nephrotoxicity was significantly different between the 2 groups. There was no significant difference in the mean estimated glomerular filtration rate at 1, 3, or 5 years after transplantation between the 2 groups. Conclusion: In total, 37.5% of 1-year protocol biopsies showed histological evidence of medullary ray injury. This finding suggests that CNI nephrotoxicity might be the main contributor to medullary ray injury in 1-year protocol biopsies. The presence of medullary ray injury had little influence on renal function, at least during the first 5 years after transplantation.
- 27 March 2019
- Published by Wiley in Nephrology
- Vol. 24 (4) , 450-455
Management of patients with severe Epstein syndrome: Review of four patients who received living‐donor renal transplantation
Aim: Epstein syndrome is a hereditary disease characterized by macrothrombocytopaenia and progressive nephritis. The abnormality of the MYH9 gene has a strong relationship to the severity of the disease. Severe Epstein syndrome progresses to end‐stage renal disease rapidly after adolescence. There is no established therapy. We sought to clarify appropriate management of Epstein syndrome nephropathy.Methods: Epstein syndrome patients who underwent renal transplantation at our institution between March 2009 and March 2017 were enrolled. Epstein syndrome was diagnosed based on clinical features and genetic testing. Patient medical records were reviewed retrospectively.Results: Four male patients with Epstein syndrome, all with severe MYH9 gene mutations (p.R702C in three and p.S96L in one), were enrolled. Despite treatment with renin–angiotensin system blockers, nephropathy was refractory and progressed rapidly, and the patients required dialysis or renal transplantation after adolescence. Early preparation for treatment based on early and accurate diagnosis of Epstein syndrome enabled two patients to undergo pre‐emptive renal transplantation. For these patients, we kept the platelet count above 100 × 109/L until day 7 after renal transplantation with platelet transfusions for macrothrombocytopaenia, and no postoperative bleeding episodes occurred.Conclusion: Epstein syndrome nephropathy due to a severe MYH9 gene mutation can be refractory and progress rapidly; therefore, early and accurate diagnosis is important for safer therapeutic options including pre‐emptive renal transplantation. By keeping the platelet count above 100 × 109/L during the perioperative period, renal transplantation can be a safe treatment option for severe Epstein syndrome nephropathy.
- 27 March 2019
- Published by Wiley in Nephrology
- Vol. 24 (4) , 450-455
Management of patients with severe Epstein syndrome: Review of four patients who received living‐donor renal transplantation
Aim: Epstein syndrome is a hereditary disease characterized by macrothrombocytopaenia and progressive nephritis. The abnormality of the MYH9 gene has a strong relationship to the severity of the disease. Severe Epstein syndrome progresses to end‐stage renal disease rapidly after adolescence. There is no established therapy. We sought to clarify appropriate management of Epstein syndrome nephropathy.Methods: Epstein syndrome patients who underwent renal transplantation at our institution between March 2009 and March 2017 were enrolled. Epstein syndrome was diagnosed based on clinical features and genetic testing. Patient medical records were reviewed retrospectively.Results: Four male patients with Epstein syndrome, all with severe MYH9 gene mutations (p.R702C in three and p.S96L in one), were enrolled. Despite treatment with renin–angiotensin system blockers, nephropathy was refractory and progressed rapidly, and the patients required dialysis or renal transplantation after adolescence. Early preparation for treatment based on early and accurate diagnosis of Epstein syndrome enabled two patients to undergo pre‐emptive renal transplantation. For these patients, we kept the platelet count above 100 × 109/L until day 7 after renal transplantation with platelet transfusions for macrothrombocytopaenia, and no postoperative bleeding episodes occurred.Conclusion: Epstein syndrome nephropathy due to a severe MYH9 gene mutation can be refractory and progress rapidly; therefore, early and accurate diagnosis is important for safer therapeutic options including pre‐emptive renal transplantation. By keeping the platelet count above 100 × 109/L during the perioperative period, renal transplantation can be a safe treatment option for severe Epstein syndrome nephropathy.